STRATEGIC OUTLOOK The Company?s business objectives for the next 12 months are: 1. Continue…
business objectives for the next 12 months are:
Continue to build worldwide market share, distribution networks, secure new customers,
and launch new items in the natural pet product space, growing the Company?s line
of innovative supplements and natural remedy products for pets. Sales will be through
traditional distribution channels, direct-to-store and direct-to-consumer online sales
Successfully complete additional capital financingsin order to fund the objectives of the
Company?s business plan.
Complete build-out of the first part of phaseone
of the Company?s 25,000 square foot medicinal cannabis production facility located in Lumby, British Columbia, in order to comply with Health Canada?s requirements to become a licensed producer under the new Cannabis Act.
Receive approval to sell medicinal cannabis under the Cannabis Act in order to commence
the research & development and sale of cannabis-based products.
Review potential joint ventures or strategic acquisition targets in the pet,health & wellness
and cannabis space.
TRUE LEAF MEDICINE INTERNATIONAL LTD.
Management Discussion & Analysis
Month Periods Ended September 30, 2018 and September 30, 2017
(Expressed in Canadian dollars)
STRATEGIC OUTLOOK (continued)
The Company?s long-term business objectives are:
Create a global cannabis-for-pets brand, with the mission to improve the quality of life for companion animals;
Increase sales, distribution and store count within the pet specialty, mass-pet, veterinary and food/drug/mass market segments in addition to building a dedicated consumer base online;
Launch additional product lines and secure additional distribution partners in the European markets;
Seek out key distribution partners for alternative market regions like Asia, South America and other potential new markets;
Continue to perform R&D work and launch new ?CBD? pet formulations for the North American and European markets;
Seek out potential long-term strategic partners to support the business.
For TL Medicine:
Complete construction of the medicinal cannabis facility and be approved as a grower and seller of medicinal cannabis under the Cannabis Act in Canada;
Implement in-house lab and build out lab services business model;
Implement extraction, fractionation and remediation equipment;
Assess the sale/lease of space within the Lumby facility, as well as offering value-added services, supporting the micro-cultivatorcannabis community;
Assess ongoing demand and need for the build out of phase two, expanding
production capacity to a total of 10,000 kilograms of dried flower per year;
Assign capital towards research and development in order to build a base of
intellectual property from proprietary formulations, cultivars, with a focus on
unique pet product formulations and supplements;
Assess and explore opportunities to develop a base of wholesale supply
contracts for the recreational or medicinal markets.
Images are for reference only.Images gathered automatic from google.All rights on the images are with their original owners.